Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May 27;13(6):875-876.
doi: 10.1021/acsmedchemlett.2c00136. eCollection 2022 Jun 9.

Novel Halomethylketone Azadipeptides for Treating COVID-19

C S Brian Chia  1 , Yi Yang See  1
Affiliations
Editorial

Novel Halomethylketone Azadipeptides for Treating COVID-19

C S Brian Chia et al. ACS Med Chem Lett. .

Abstract

COVID-19 is a highly infectious disease caused by the SARS-CoV-2 coronavirus. It rapidly escalated into a global pandemic, causing more than 6 million fatalities by March 2022, a little over 2 years since its emergence in December 2019. The first peptidomimetic coronavirus main protease inhibitor, nirmatrelvir, was granted Emergency Use Authorization by the U.S. FDA on Dec 22, 2021. Less than a month after its patent application, Hoffmann La-Roche scientists filed a patent application describing azadipeptide peptidomimetic inhibitors (WO 2022/043374 A1). This patent highlight reveals the structure-activity relationship of key azadipeptide inhibitors described in the patent.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

References

    1. Banerjee R.; Perera L.; Tillekeratne L. M. V. Potential SARS-CoV-2 main protease inhibitors. Drug Discovery Today. 2021, 26, 804.10.1016/j.drudis.2020.12.005. - DOI - PMC - PubMed
    1. Chia C. S. B. Novel Nitrile Peptidomimetics for Treating COVID-19. ACS Med. Chem. Lett. 2022, 13, 330.10.1021/acsmedchemlett.2c00030. - DOI - PMC - PubMed

Publication types